Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00149136
Status:
UNKNOWN
Last Update Posted:
2007-04-27
First Post:
2005-09-06
Brief Title:
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia Ph ALL in the Elderly With Imatinib Mesylate STI571 and Chemotherapy
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Evaluation of Imatinib GLIVEC After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia Ph ALL a Non Randomised Controlled Open Multicentric International Phase II Clinical Study CSTI 571 AFR09 Trial
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ALL patients aged 55 years or older were treated with steroids during one week and Phve cases were then offered a specific therapy including an induction treatment with steroids cyclophosphamide daunorubicin and vincristine followed irrespective of response to induction chemotherapy by imatinib 600 mg daily combined with intermittent steroids during 2 months Patients in complete response CR were then given 10 blocks of alternating chemotherapy including 2 additional two-month blocks of imatinib for a total treatment duration of 2 years Therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation
Duration of therapy 2 years
Duration of therapy 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None